Retrospective analysis shows higher absolute lymphocyte count predicts improved survival in large B-cell lymphoma, indicating its role as a biomarker for therapeutic strategies.
Key Points
Improved progression-free survival is associated with lymphocyte counts above 1.0 x 10⁹/L in large B-cell lymphoma patients.
Analysis of median overall survival revealed key metrics linked to lymphocyte count post-salvage therapies.
Retrospective study included 352 large B-cell lymphoma patients receiving CAR T therapy and subsequent salvage treatments.
Findings highlight risk stratification and treatment outcomes, underscoring the potential for lymphocyte count in patient management.